A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-negative Inflammatory Breast Cancer (IBC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Inflammatory breast cancer
- Focus Therapeutic Use
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2018 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 24 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.